In this regard, Spathis and co-workers (2017) designed a synthetic RXRα/Nurr1 agonist BRF110, for pharmacological activation of Nurr1, which can potentially serve as a monotherapy and has shown promising effects in PD models [11]. Here, NR4A2 is linked to Parkinson disease.